CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Ethambutol/isoniazid/pyrazinamide/rifampicin

tuberculosis treatment

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionJul 15, 2025
Entity authorityQ28163603 ↗
Source-derived summary

Ethambutol/isoniazid/pyrazinamide/rifampicin, also known as ethambutol/isoniazid/pyrazinamide/rifampin, is a medication used for tuberculosis. It is a fixed dose combination of ethambutol, isoniazid, pyrazinamide, and rifampicin. It is used either alone or with other antituberculosis medication. It is taken by mouth.

Side effects are those of the underlying medications. Pyridoxine may be used to decrease the risk of numbness. It is not recommended in people with liver problems or severe kidney problems. Use may not be suitable in children. It is unclear if use during pregnancy is safe.

It is on the World Health Organization's List of Essential Medicines.

Editorial summary

This brief starts where responsible research should: with the source description of “Ethambutol/isoniazid/pyrazinamide/rifampicin” as tuberculosis treatment. Everything that follows is an evidence route, not borrowed authority.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current 96-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. The account is most persuasive where Ethambutol, isoniazid and pyrazinamide can be independently traced.
Editorial analysis

Why this record matters

The subject matters to the general reference register because the source frames it as tuberculosis treatment. Its deeper value depends on whether names, dates, institutions and citations support that framing.

Evidence profile

The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jul 15, 2025. The linked authority identifier is Q28163603. None of the 0 selected statements returned an explicit reference.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Ethambutol/isoniazid/pyrazinamide/rifampicin”, its source revision and the description used here.
  2. Expand the search: follow Ethambutol/isoniazid/pyrazinamide/rifampicin primary sources, Ethambutol/isoniazid/pyrazinamide/rifampicin archive and Ethambutol research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Ethambutol/isoniazid/pyrazinamide/rifampicin”?
  2. What terminology or title could unlock a more precise catalogue search?
  3. Which cited source is closest to the event, object or claim?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Ethambutol/isoniazid/pyrazinamide/rifampicin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.